{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-007253","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.095934+00:00","generated_at":"2026-05-21T23:17:32.191408+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ProMIS Q1 net loss $7.3M; completes first cohort enrollment in PRECISE-AD trial","bullets":["Net loss $7.3M vs $3.6M YoY; R&D expense $5.5M on PMN310 Phase 1b trial costs.","Cash $8.4M at March 31, 2025, down from $13.3M at Dec 31, 2024.","First cohort fully enrolled and dosed in PRECISE-AD (Phase 1b) for PMN310 in Alzheimer's.","Six-month interim results expected 1H 2026; topline data by end of 2026.","PRECISE-AD designed to detect ARIA with 95% confidence; powered for biomarker changes at 6 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-007253","json":"https://secwatch.observer/filing/0001558370-25-007253.json","markdown":"https://secwatch.observer/filing/0001558370-25-007253.md","text":"https://secwatch.observer/filing/0001558370-25-007253.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000155837025007253/0001558370-25-007253-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000155837025007253/pmn-20250512x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:17:32.191408+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}